Ultime notizie per Hippo Holdings (NYSE:HIPO) Azioni

Hippo Holdings

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the Company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Hippo Holdings Inc

<p>Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) reported quarterly sales of $44.700 which missed the analyst consensus estimate of $44.900 million by 100.00 percent.  This is a 100.00 percent decrease over sales of $41.324 million the same period last year.</p>


Earnings

Earnings Misses

News

SAND

Sandstorm Gold Q3 Sales $44.700 Miss $44.900M Estimate

<p>nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year.  The company reported quarterly sales of $56.13 million which beat the analyst consensus estimate of $55.27 million by 1.55 percent.  This is a 10.85 percent increase over sales of $50.63 million the same period last year.</p>


Earnings Beats

LASR

nLight Q3 Adj $(0.08), Inline, Sales $56.13M Beat $55.27M Estimate

<p>Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) is looking for Q2 Adj EPS of $0.30-0.40 vs $0.27 analyst estimate. sees sales of $380.000 million-400.000 million vs $354.32 million estimate.</p>


Guidance

LITE

Lumentum Holdings Sees Q2 Adj EPS $0.30-0.40 vs $0.27 Est; Sees Sales $380.000M-400.000M vs $354.32M Est

<p>Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent.</p>


Consolidated Edison Q3 2024 Adj. EPS $1.68 Beats $1.62 Estimate

<p>PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent.  The company reported quarterly sales of $46.409 million which beat the analyst consensus estimate of $46.196 million by 0.46 percent.  This is a 9.58 percent increase over sales of $42.350 million the same period last year.</p>


PDFS

PDF Solutions Q3 2024 Adj. EPS $0.25 Beats $0.20 Estimate, Sales $46.409M Beat $46.196M Estimate

<p>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) affirms FY2024 sales outlook from $74.50 million-76.50 million to $74.50 million-76.50 million.</p>


TELA

TELA Bio Affirms FY2024 Sales Guidance from $74.50M-76.50M to $74.50M-76.50M

<p>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2025 Product sales outlook from $450.00 million-475.00 million to $450.00 million-475.00 million.</p>


IOVA

Iovance Biotherapeutics Affirms FY2025 Product Sales Guidance from $450.00M-475.00M to $450.00M-475.00M

<p>Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.</p>


COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

CPAY

Corpay Expects Q4 Total Revenues Of $1.04B - $1.07B, Adjusted EP Of $5.25 - $5.45

<p>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2024 Product sales outlook from $160.00 million-165.00 million to $160.00 million-165.00 million.</p>


Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance from $160.00M-165.00M to $160.00M-165.00M

<p>AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 33.33 percent increase over earnings of $0.03 per share from the same period last year.  The company reported quarterly sales of $82.68 million which missed the analyst consensus estimate of $92.83 million by 10.93 percent.  This is a 10.60 percent decrease over sales of $92.48 million the same period last year.</p>


ASLE

AerSale Q3 Adj $0.04 Misses $0.05 Estimate, Sales $82.68M Miss $92.83M Estimate

<p>Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent.  The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent.  This is a 180.74 percent increase over sales of $2.798 million the same period last year.</p>


AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

<p>Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) sees Q4 sales of $6.000 million-6.300 million vs $5.95 million estimate.</p>


INVE

Identiv Sees Q4 Sales $6.000M-6.300M vs $5.95M Est

<p><strong>Fourth Quarter 2024 Outlook</strong></p>
<p>For the fourth quarter 2024, the Company expects:</p>
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>


WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

<p>Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.13 by 169.23 percent.  The company reported quarterly sales of $52.224 million which beat the analyst consensus estimate of $36.113 million by 44.61 percent.  This is a 135.57 percent increase over sales of $22.169 million the same period last year.</p>


INOD

Innodata Q3 2024 Adj. EPS $0.35 Beats $0.13 Estimate, Sales $52.224M Beat $36.113M Estimate

ABNB

Airbnb Sees Q4 2024 Revenue $2.39B-$2.44B Vs $3.717B Est.

<p>Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 39.33 percent increase over losses of $(0.89) per share from the same period last year.  The company reported quarterly sales of $28.07 million which beat the analyst consensus estimate of $28.02 million by 0.20 percent.  This is a 26.41 percent increase over sales of $22.21 million the same period last year.</p>


OUST

Ouster Q3 EPS $(0.54) Beats $(0.57) Estimate, Sales $28.07M Beat $28.02M Estimate

AFRM

Affirm Sees FY25 GMV OF More Than $34B

<p>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year.  The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent.  This is a 9.82 percent decrease over sales of $3.299 million the same period last year.</p>


AXDX

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The financial technology (FinTech) industry is forecasted to grow at an annualized rate of <a href="https://www.fortunebusinessinsights.com/fintech-market-108641" target="_blank">16.5%</a> until 2032, illustrating its potential. However, information about the bulk of financial <a href="https://investorplace.com/industries/technology/">technology stocks</a> is widely dispensed. As such, most <a href="https://investorplace.com/industries/financial/fintech/">FinTech stocks</a> are either priced in or overvalued.</p>



<p>Considering the above, I decided to embark on a journey to find three overlooked fintech stocks worth investing in. Methodologically, I focused on fundamental aspects, valuation multiples, and key operating metrics. Moreover, I emphasized event-driven elements to ensure that each stock was analyzed holistically.</p>



<p>Some investors might find FinTech stocks too risky. However, if you are willing and able to take on risk, here are three overlooked fintech stocks worth considering.</p>



<h2>MoneyLion (ML)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/moneylion-fuse-1600-300x169.jpg" alt="MoneyLion Iphone Display"><div>Source: Sulastri Sulastri / Shutterstock.com</div></div><p><strong>MoneyLion</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/ml-stock-quote/"><strong>ML</strong></a></span>) is a loan intermediary servicing lower credit score borrowers. The company operates a novel business model, integrated with more than <a href="https://d1io3yog0oux5.cloudfront.net/_aa329c02c6b801b61f0daec1556d57f0/moneylion/db/1912/17912/pdf/Q1+2024+Earnings+Presentation_vF.pdf">1,100 external partners</a> to facilitate fee-based loan revenue, advertising revenue, and subscription-geared income. Moreover, MoneyLion has adopted best-in-class machine learning technology, allowing it to assess numerous data points before intermediating loans or adopting an advertiser onto its platform.</p>



<p>The company recently proved its worth when it released its first-quarter earnings report. MoneyLion exceeded its revenue estimate by <a href="https://seekingalpha.com/news/4101031-moneylion-gaap-eps-of-0_60-beats-0_68-revenue-of-121m-beats-4_69m?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A5">$4.69 million</a>. Additionally, its earnings-per-share settled 68 cents above target, conveying its bottom-line efficiency.</p>



<p>According to CNN, ML stock has merely <a href="https://edition.cnn.com/markets/stocks/ML">four ratings</a> from Wall Street, illustrating that it has yet to draw the attention of most analysts. Moreover, key metrics suggest that ML stock is grossly undervalued. For example, it has a price-to-sales ratio of merely <a href="https://finance.yahoo.com/quote/ML/key-statistics/">1.7x</a>, which is low for a growth stock.</p>



<p>I&rsquo;m bullish here!</p>



<h2>NerdWallet (NRDS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/nrds-stock-1-300x169.jpg" alt="The NerdWallet (NRDS) logo displayed on a computer screen."><div>Source: monticello / Shutterstock.com</div></div><p><strong>NerdWallet</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nrds-stock-quote/"><strong>NRDS</strong></a></span>) operates a financial information platform. The firm&rsquo;s platform compares and assesses numerous financial products ranging from personal finance to niche investing. Although NRDS stock probably won&rsquo;t achieve mega-cap status, its business model is aligned with today&rsquo;s world, which includes growth in retail investor participation and demand for financial literacy. As such, I think NRDS stock can reach new heights in the coming years.</p>



<p>As for its key metrics, NerdWallet possesses a scintillating three-year compound annual growth rate of <a href="https://seekingalpha.com/symbol/NRDS/growth">34.19%</a>. Moreover, NerdWallet has a gross profit margin of <a href="https://seekingalpha.com/symbol/NRDS/profitability">90.81%</a>, suggesting it has inflation pass-through abilities. Sure, the company has yet to achieve profitability. However, it remains focused on growth and will likely emphasize shareholders&rsquo; residual value when the time is right.</p>



<p>According to MarketWatch, NRDS stock has <a href="https://www.marketwatch.com/investing/stock/nrds/analystestimates">seven Wall Street ratings</a>. Although this is not a negligent number of ratings, it remains low, suggesting NRDS stock has yet to gain much traction among Wall Street analysts. Moreover, NRDS stock has a price-to-sales ratio of <a href="https://finance.yahoo.com/quote/NRDS/key-statistics/">1.8x</a>, implying that it is undervalued, especially given its resilient growth rate.</p>



<h2>Hippo Holdings (HIPO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/06/health_insurance_1600-300x169.jpg" alt="A health insurance claim form with a stethoscope, a calculator, and several hundred dollar bills resting on top."><div>Source: Valeri Potapova / Shutterstock.com</div></div><p><strong>Hippo Holdings</strong> (NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/hipo-stock-quote/">HIPO</a></strong>) is an insurance technology company geared toward short-term solutions such as property and casualty insurance. I&rsquo;m a massive fan of online insurance technology as it addresses consumer convenience. Moreover, Hippo has formed a comprehensive suite of partnerships, allowing it to benefit from synergies while providing its customers with an integrated process.</p>



<p>The company proved its worth upon releasing its first-quarter fiscal report in May. Hippo strolled past estimates by delivering a revenue beat of <a target="_blank" href="https://seekingalpha.com/news/4098373-hippo-holdings-reports-q1-results?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A2">$12.12 million</a>, a 1.14x year-over-year increase! Moreover, Hippo trimmed its net loss by 49% to $36 million.</p>



<p>Similar to the other stocks mentioned in this article, HIPO has earned a low of outstanding Wall Street ratings. In fact, it has merely <a target="_blank" href="https://www.marketwatch.com/investing/stock/hipo/analystestimates">five ratings</a> from Wall Street analysts, showing that it is somewhat under the radar. Additionally, HIPO stock&rsquo;s price-to-sales ratio of 1.5x, which is low if one considers its secular growth attributes.</p>



<p><em>On the date of publication, Steve Booyens did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Steve Booyens co-founded Pearl Gray Equity and Research in 2020 and has been responsible for cross-asset research and PR ever since. Before founding the firm, Steve spent time working in various finance roles in London and South Africa. He holds an MSc in Investment Banking from Queen Mary &ndash; University of London. Furthermore, Steve obtained his CFA Charter on April 26, 2024, and is working toward his Ph.D. in Finance. His articles are published on various reputable web pages such as Seeking Alpha, TipRanks, Yahoo Finance, and Benzinga. Steve&rsquo;s articles on InvestorPlace form an interesting juxtaposition between mainstream opinion and objective theory. Readers can expect coverage on frequently traded stocks, REITs, fixed-income funds, CEFs, and ETFs.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/treasure-hunt-3-fintech-stocks-wall-street-hasnt-discovered-yet/">Treasure Hunt: 3 Fintech Stocks Wall Street Hasn&#8217;t Discovered Yet</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Treasure Hunt: 3 Fintech Stocks Wall Street Hasn't Discovered Yet

Jefferies analyst Yaron Kinar maintained a Buy rating on Hippo Holdings (HIPO – Research Report) today and set a price target of $24.00. The compan...

Jefferies Sticks to Their Buy Rating for Hippo Holdings (HIPO)

Hippo Holdings Q2 2024 Earnings Preview

Hippo Holdings reports Q2 results

Hippo Holdings, Inc. (HIPO) Q2 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Hippo Holdings</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/hipo-stock-quote/"><strong>HIPO</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Hippo Holdings reported earnings per share of -$1.64. This was below the analyst estimate for EPS of -$1.45.</li><li>The company reported revenue of $89.60 million.</li><li>This was 2.55% better than the analyst estimate for revenue of $87.37 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/hipo-stock-earnings-hippo-holdings-for-q2-of-2024/">HIPO Stock Earnings: Hippo Holdings Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

HIPO Stock Earnings: Hippo Holdings Misses EPS, Beats Revenue for Q2 2024

In a report released yesterday, Thomas McJoynt Griffith from KBW maintained a Hold rating on Hippo Holdings (HIPO – Research Report), with a price ...

KBW Remains a Hold on Hippo Holdings (HIPO)

JMP Securities analyst Matthew Carletti reiterated a Buy rating on Hippo Holdings (HIPO – Research Report) today and set a price target of $25.00. ...

JMP Securities Reaffirms Their Buy Rating on Hippo Holdings (HIPO)

KBW analyst Thomas McJoynt Griffith maintained a Hold rating on Hippo Holdings (HIPO – Research Report) yesterday and set a price target of $21.00....

KBW Sticks to Their Hold Rating for Hippo Holdings (HIPO)

Hippo Holdings ( ($HIPO) ) has provided an announcement. Yuval Harry, the former Chief Revenue Officer of Hippo Holdings Inc., is set to leave his ...

Hippo Holdings CRO Transition with Consulting Continuation

HIPO

NRDS

Insurance

Press Releases

Hippo Reports Fourth Quarter 2023 Financial Results

Hippo's First Connect Hits 100 Carrier & MGA Milestone and Launches New Appetite Finder Feature

HIPPO TO REPORT FIRST QUARTER FINANCIAL RESULTS ON MAY 2, 2024

Vareto Introduces First Multiplayer Platform In Enterprise Planning Category

Hippo Reports First Quarter 2024 Financial Results

HIPPO TO REPORT SECOND QUARTER FINANCIAL RESULTS ON AUGUST 8, 2024

Hippo Reports Second Quarter 2024 Financial Results

Real Estate

Hippo Expands Home Builder Access to New Homes Program in California, Florida, and Texas

Hippo Appoints William Malone as Vice President, Head of Agency

HIPPO TO REPORT THIRD QUARTER FINANCIAL RESULTS ON NOVEMBER 8, 2024

Abacus Life

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hagerty

Huize Holding Limited - American Depositary Shares

Huize Holding

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Hldgs

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Comments

Hippo Holdings

Notizie

Ultime notizie per Hippo Holdings (NYSE:HIPO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO